Earnings ·
NewAmsterdam Pharma Company N.V. reported financial results for the quarter ended June 30, 2026, announcing a net loss…
NAMSNewAmsterdam Pharma Co N.V.
NewAmsterdam Pharma Company N.V. reported financial results for the quarter ended June 30, 2026, announcing a net loss of $64.1 million and revenue of $3.7 million. The company holds $678.3 million in cash, cash equivalents, and marketable securities. Clinically, NewAmsterdam received a positive CHMP opinion from the European Medicines Agency recommending marketing authorization for obicetrapib and its combination with ezetimibe for treating primary hypercholesterolemia or mixed dyslipidemia. The firm plans to announce an interim analysis of its Phase 3 PREVAIL cardiovascular outcomes trial in the fourth quarter of 2026, with results expected in the first quarter of 2027. Additionally, topline data from the Phase 3 RUBENS trial is anticipated by year-end 2026. NewAmsterdam Pharma Company N.V. operates as a late-stage biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease with elevated LDL-C.